Beck Bode LLC Invests $13.18 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Beck Bode LLC purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 56,017 shares of the biopharmaceutical company's stock, valued at approximately $13,181,000. Alnylam Pharmaceuticals makes up about 2.4% of Beck Bode LLC's portfolio, making the stock its 24th biggest holding.

A number of other hedge funds have also added to or reduced their stakes in ALNY. Jennison Associates LLC bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $61,160,000. Strategic Financial Concepts LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $41,529,000. Truist Financial Corp boosted its stake in shares of Alnylam Pharmaceuticals by 136.6% in the 4th quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock worth $1,035,000 after buying an additional 2,539 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 3.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock valued at $67,464,000 after acquiring an additional 8,462 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in Alnylam Pharmaceuticals by 13.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company's stock worth $4,687,000 after acquiring an additional 2,285 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ALNY. William Blair reissued an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. StockNews.com lowered shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Wednesday. Stifel Nicolaus boosted their target price on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research note on Monday, March 31st. Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. Finally, Sanford C. Bernstein dropped their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have issued a buy rating to the company's stock. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $319.17.

Insiders Place Their Bets

In related news, CMO Pushkal Garg sold 1,561 shares of the company's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $398,320.37. Following the completion of the transaction, the chief marketing officer now directly owns 13,537 shares in the company, valued at approximately $3,454,236.29. The trade was a 10.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the sale, the executive vice president now owns 12,881 shares in the company, valued at $3,240,344.36. The trade was a 10.06 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 7,392 shares of company stock worth $1,875,627 in the last ninety days. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $259.39 on Friday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $144.73 and a 12 month high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The stock has a market cap of $33.74 billion, a P/E ratio of -119.53 and a beta of 0.17. The company has a 50 day moving average of $248.21 and a 200 day moving average of $254.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The firm had revenue of $594.19 million for the quarter, compared to analysts' expectations of $584.32 million. During the same quarter in the prior year, the firm posted ($0.16) earnings per share. The business's revenue for the quarter was up 20.2% on a year-over-year basis. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.